Printer Friendly

UPJOHN CONSUMER PRODUCTS DIVISION ENTERS INTO MARKETING AGREEMENT WITH MCNEIL CONSUMER PRODUCTS COMPANY

 KALAMAZOO, Mich., Jan. 18 /PRNewswire/ -- The Upjohn Company (NYSE: UPJ) and McNeil Consumer Products Company announced today that the two companies have agreed in principle to a U.S. marketing agreement involving Upjohn's nonprescription analgesic brand, Motrin IB.
 McNeil would grant Upjohn access to certain McNeil product developments, including several ibuprofen-based products developed by McNeil but not marketed, as well as merchandising services to be performed by McNeil for Motrin products. McNeil would receive financial considerations and some future technology.
 Thomas M. Laughlin, corporate vice president and general manager of Upjohn's Consumer Products Division, said, "This is further evidence of Upjohn's commitment to become a major force in the nonprescription pharmaceutical industry."
 James T. Lenehan, president of McNeil Consumer Products Company, said, "We believe this marketing agreement will significantly benefit both companies and we look forward to working with Upjohn."
 Further details of the agreement were not disclosed.
 Motrin became available without a prescription as Motrin IB in 1989 and is marketed in 200 mg tablets and caplets.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 McNeil Consumer Products is a Johnson & Johnson (NYSE: JNJ) affiliate specializing in nonprescription pharmaceuticals, headquartered in Fort Washington, Pa.
 -0- 1/18/93
 /CONTACT: Nancy H. Lassen of The Upjohn Company, 616-323-6902; or Robert Kniffin of McNeil Consumer Products Company, 908-524-3535/
 (UPJ JNJ)


CO: The Upjohn Company; McNeil Consumer Products Company ST: Michigan, Pennsylvania IN: MTC SU: LIC

SM -- DE016 -- 5992 01/18/93 16:22 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 18, 1993
Words:276
Previous Article:CHEMICAL FINANCIAL CORPORATION ANNOUNCES 1992 OPERATING RESULTS
Next Article:OLD KENT ACHIEVES ITS 20TH CONSECUTIVE YEAR OF RECORD EARNINGS
Topics:


Related Articles
ARTHRITIS FOUNDATION ANNOUNCES AGREEMENT WITH McNEIL CONSUMER PRODUCTS COMPANY
GENEVA PHARMACEUTICALS AND UPJOHN EXTEND AGREEMENT
MCNEIL CONSUMER PRODUCTS NAMED AS NEW DISTRIBUTOR OF CYGNUS' NICOTINE PATCH IN THE U.S. AND CANADA
UPJOHN TO DEVELOP ANTI-CANCER AGENT FROM JAPAN
MGI PHARMA GRANTS CANADIAN RIGHTS FOR SALAGEN(R) TABLETS TO UPJOHN CANADA
MGI PHARMA, INC. ANNOUNCES TAIWAN DISTRIBUTOR OF SALAGEN(R) TABLETS AT 1995 ANNUAL MEETING OF SHAREHOLDERS
UPJOHN AND GENSIA RESTRUCTURE MULTISOURCE ONCOLYTIC DRUG ALLIANCE
CONSUMERS POWER SIGNS LONG-TERM ELECTRIC SALES AGREEMENT WITH PHARMACIA & UPJOHN, INC.
Pharmacia & Upjohn to Purchase U.S. Manufacturing Rights for NICOTROL(R) From Cygnus
Pharmacia & Upjohn and John Paul Mitchell Systems Announce;.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters